STAT+: Pharmalittle: German regulator eyes Ozempic export ban amid shortages; NIH-funded clinical trials lagging pharma’s in enrollment
STAT
NOVEMBER 15, 2023
Just consider the alternatives. … The German drug regulator is considering an export ban on Novo Nordisk’s diabetes drug Ozempic, which is in high demand for weight-loss, as European health systems grapple to stem a supply shortage , Reuters writes. We are doing just fine, thank you.
85 
Let's personalize your content